August saw 29 companies join Crunchbase's Unicorn Board, adding approximately $63 billion in valuation to the tracked cohort. What distinguishes this cohort from previous months is composition: AI software and semiconductor startups represented more than one-third of the new unicorns—a significant shift from historical patterns where venture funding distributed more evenly across sectors. Notably, more than 35 percent of August's unicorn class was under three years old, suggesting that companies building foundational AI infrastructure and chip technology are reaching billion-dollar valuations at unprecedented velocity. This concentration reflects a fundamental reallocation of capital within venture markets, where investors are placing increasingly large bets on fewer, more specialized categories.
The velocity of AI-infrastructure scaling has caught the attention of top-tier venture firms, who are now aggressively pursuing early-stage plays in this space. Mighty Capital's SC Moatti recently argued that traditional competitive moats—proprietary data, first-mover advantage, patents—no longer insulate AI startups from commoditization. Instead, the firms backing August's unicorns are betting on counter-positioning and network effects: companies that solve structural problems in ways incumbents cannot, or that build ecosystems where value compounds with each new participant. This thesis helps explain why semiconductor and AI-software startups are outpacing other emerging categories. They sit at the foundation of the AI stack, where network effects and switching costs run deepest. A successful inference-optimization startup or specialized chip designer creates dependencies across the entire startup ecosystem.
However, this capital concentration comes against a backdrop of significant venture fragmentation elsewhere. U.S. tech companies cut over 127,000 jobs in 2025, and layoffs have continued into 2026, according to Crunchbase's layoffs tracker. Meanwhile, hiring-platform Incredible Health raised funding by positioning itself at the intersection of healthcare scarcity and venture interest in vertical SaaS solutions—suggesting capital still flows to startups solving acute operational problems in overlooked sectors. Yet the divergence is stark: Series A funding for non-AI enterprise software, biotech outside immunotherapy, and consumer startups has contracted sharply. The unicorn board's August composition signals that venture capital has crystallized around a bet: infrastructure-layer AI and semiconductor companies will generate the highest returns, even as capital remains scarce for applications, services, and infrastructure-agnostic startups.